Amiloride News and Research

RSS

Exploring the possibility of whether surface ACE2 carried by extracellular vesicles can facilitate SARS-CoV-2 infection

Researchers explored whether surface ACE2 carried by EVs can facilitate the entry of SARS-CoV-2 into host cells.

20 May 2022

Complex RNA structures could have untapped therapeutic potential in the fight against COVID-19

To the untrained eye, the loops, kinks and folds in the single strand of RNA that makes up the coronavirus genome look like a jumble of spaghetti or tangled yarn. But to researchers like Amanda Hargrove, a chemistry professor at Duke University, the complex shapes that RNA takes on as it folds upon itself could have untapped therapeutic potential in the fight against COVID-19.

26 Nov 2021

Computational study identifies human proteins structurally similar to SARS-CoV-2 proteins

A new study published in Scientific Reports identifies the human proteins that share structural similarities with the SARS-CoV-2 proteins.

30 Aug 2021

Synthesis of photocatalytic and antibacterial materials for removing medicines from wastewater

The Theoretical and Computational Chemistry Laboratory (QTC) of the Jaume I University of Castellón (UJI), in collaboration with the Centre for the Development of Functional Materials (CDMF) of the Universidad Federal de São Carlos (UFSCar), has published an article entitled “Selective Synthesis of α-, β-, and γ-Ag2WO4 Polymorphs: Promising Platforms for Photocatalytic and Antibacterial Materials” in scientific journal Inorganic Chemistry, which showcases new photocatalytic and antibacterial materials to remove medicines from wastewater.

15 Mar 2021

Amilorides reduce SARS-CoV-2 viral replication in vitro

A new U.S. study published on the bioRxiv preprint server reports the use of an amiloride-based scaffold that targets a viral RNA structure known to be essential in viral replication in the 5’-untranslated region (UTR) of the virus. The researchers say this heralds the application of these molecules as chemical probes to explore viral biology and produce specific antivirals targeting RNA regions of the coronavirus genome.

8 Dec 2020

MIT researchers unravel the molecular structure of key coronavirus protein

MIT chemists have determined the molecular structure of a protein found in the SARS-CoV-2 virus. This protein, called the envelope protein E, forms a cation-selective channel and plays a key role in the virus's ability to replicate itself and stimulate the host cell's inflammation response.

12 Nov 2020

Clinical trial advances treatment for multiple sclerosis

Researchers conducting a clinical trial to advance the treatment of multiple sclerosis successfully applied a new drug testing methodology which allows several treatment options to be trialled at once.

27 May 2020

Inhaled form of high blood pressure drug has potential to treat anxiety, pain

An inhaled form of a high blood pressure medication has potential to treat certain types of anxiety as well as pain, according to a new study by the Centre for Addiction and Mental Health.

11 Sep 2018

Researchers use simple blood tests to improve treatment for resistant hypertension in Africa

Using two simple blood tests, Western University researchers were able to drastically improve treatment for resistant hypertension across three sites in Nigeria, Kenya and South Africa.

2 May 2017

PATHWAY 3 study: Half dose combination of common diuretics reduces blood pressure

The combination of two commonly used diuretics, each at half dose, can significantly reduce blood pressure without the side-effects caused by full doses of either alone, researchers from the PATHWAY 3 study have found.

31 Aug 2015

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension.

8 Dec 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

Amiloride News and Research

Exploring the possibility of whether surface ACE2 carried by extracellular vesicles can facilitate SARS-CoV-2 infection

Complex RNA structures could have untapped therapeutic potential in the fight against COVID-19

Computational study identifies human proteins structurally similar to SARS-CoV-2 proteins

Synthesis of photocatalytic and antibacterial materials for removing medicines from wastewater

Amilorides reduce SARS-CoV-2 viral replication in vitro

MIT researchers unravel the molecular structure of key coronavirus protein

Clinical trial advances treatment for multiple sclerosis

Inhaled form of high blood pressure drug has potential to treat anxiety, pain

Researchers use simple blood tests to improve treatment for resistant hypertension in Africa

PATHWAY 3 study: Half dose combination of common diuretics reduces blood pressure

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Sodium channel-blocking agent shows promise as a potential treatment for cystic fibrosis

New target for MS treatment found using old drug

Hypertension drugs may prevent Alzheimer's Disease

Salt water treatment for cystic fibrosis both effective and cheap

Amiloride and spironolactone may help patients with high blood pressure

Arrayed CRISPR Screening for Revolutionizing Target Discovery

Innovations in baculovirus–insect cell expression systems

Compound Management and its Crucial Role in Early Pharmaceutical Research

Latest News